Xeris Biopharma Holdings (XERS) Debt Ratio (2020 - 2026)

Xeris Biopharma Holdings' Debt Ratio history runs 7 years deep, the most recent figure standing at 0.56 for Q1 2026.

• Quarterly Debt Ratio fell 26.35% year-over-year to 0.56 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.56 (down 26.35% YoY) and the FY2025 annual result came in at 0.57, down 24.92% from the prior year.
• Debt Ratio was 0.56 for Q1 2026 at Xeris Biopharma Holdings, down from 0.57 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.77 in Q1 2025 and bottomed at 0.41 in Q1 2022.
• A 5-year average of 0.61 and a median of 0.62 in 2023 frame the typical range for Debt Ratio.
• Peak annual rise in Debt Ratio reached 87.66% in 2022, while the deepest fall reached 31.6% in 2022.
• Xeris Biopharma Holdings' Debt Ratio stood at 0.54 in 2022, then grew by 9.0% to 0.59 in 2023, then gained by 29.29% to 0.77 in 2024, then slipped by 24.92% to 0.57 in 2025, then retreated by 1.77% to 0.56 in 2026.
• Business Quant data shows XERS's Debt Ratio at 0.56 in Q1 2026, 0.57 in Q4 2025, and 0.59 in Q3 2025.